Restor3d completed its acquisition of Conformis, accoring to a Sept. 5 news release.
The deal was announced in June, and Conformis was valued at $2.27 per share. Conformis' board of directors unanimously approved the transaction, saying that it is in the best interests of company stockholders.
"With the addition of Conformis to the organization, we see tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopedic landscape, including shoulder, foot & ankle, spine and large joints such as knees and hips," J. Kurt Jacobus, CEO of Restor3d, said in the release. "We have mapped out a product roadmap that will deepen and extend our offerings across the body, providing surgeons and patients with the personalized device solutions they deserve."